Anktiva plus BCG outperforms BCG alone in newly treated high-risk bladder cancer – ImmunityBio
ImmunityBio, Inc. announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled, registrational trial evaluating intravesical Anktiva (nogapendekin… read more.


